Company
Arbele is a locally grown pharmaceutical biotech with over 30 scientists and staff focused on immunotherapy of advanced gastrointestinal cancers with a high mortality rate (such as liver, stomach, pancreas, oesophagus, colon and lung). The company is founded by accomplished, well-recognized scientists and senior executives from the pharmaceutical industry and teamed up with experienced professionals in business, accounting, finance and legal.
Arbele’s vision is to early detect and defeat gastrointestinal (GI) cancers with immunotherapeutics with breakthrough innovation. We strive to provide the first-in-class and best-in-class GI cancer drugs and premium in-vitro diagnostics for early disease intervention. Our exclusive worldwide patent coverage of CDH17, a novel target specific to the GI tract, means that we will be one of the leaders in the GI cancer field in providing a better, safer and cheaper treatment option to patients based on our range of robust pipelines on therapeutics and diagnostics products.
For more information: http://www.arbelebio.com
